证券代码：839273 证券简称：一致魔芋 公告编号：2025-058 湖北一致魔芋生物科技股份有限公司 第三届董事会第二十三次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 26 日 2.会议召开地点：公司会议室 3.会议召开方式：现场+通讯 4.发出董事会会议通知的时间和方式：2025 年 4 月 21 日以通讯方式发出 5.会议主持人：董事长吴平女士 6.会议列席人员：全体监事 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》《公司章程》《董事会议事规则》的相 关规定。 根据《公司法》《证券法》《北京证券交易所上市规则》等法律法规及《公司 章程》有关规定，公司已编制完成《2025 年第一季度报告》。 具体内容请详见公司于 2025 年 4 月 28 日在北京证券交易所信息披露平台 （https://www.bse.cn）披露的《2025 年一季度报告》（公告编号：2025-0 ...

Financial Performance - Net profit attributable to shareholders for Q1 2025 was CNY 22,701,930.67, representing a 36.95% increase year-over-year[10] - Operating revenue for Q1 2025 reached CNY 152,092,618.50, up 35.03% from the same period last year[10] - The weighted average return on equity increased to 3.60% from 2.89% year-over-year, indicating improved profitability[10] - The company's net profit for Q1 2025 reached CNY 22,343,832.68, a 34.1% increase compared to CNY 16,630,218.91 in Q1 2024[43] - Operating revenue for Q1 2025 was CNY 140,883,610.79, up 31.3% from CNY 107,239,654.12 in Q1 2024[43] - The operating profit for Q1 2025 was CNY 28,918,458.74, compared to CNY 20,313,278.87 in Q1 2024, reflecting a growth of 42.5%[43] - The total comprehensive income for Q1 2025 was CNY 22,343,832.68, compared to CNY 16,630,218.91 in Q1 2024, reflecting a growth of 34.1%[44] Cash Flow and Liquidity - The net cash flow from operating activities increased by 116.06% to CNY 74,981,115.63 due to higher sales collections[10] - Operating cash flow for Q1 2025 was 67,831,785.04 CNY, a significant increase from 24,430,326.86 CNY in Q1 2024, reflecting improved operational efficiency[48] - Cash inflow from operating activities totaled 163,141,635.69 CNY in Q1 2025, compared to 130,425,449.83 CNY in Q1 2024, reflecting a 25% increase[47] - Cash and cash equivalents increased by 69.79% to CNY 99,756,393.93, attributed to increased sales receipts during the reporting period[11] - Cash and cash equivalents at the end of Q1 2025 totaled 88,325,584.18 CNY, down from 111,335,152.57 CNY at the end of Q1 2024, indicating a liquidity contraction[48] - The net increase in cash and cash equivalents for Q1 2025 was 38,944,642.00 CNY, down from 57,124,378.49 CNY in Q1 2024, indicating a slowdown in cash generation[48] Assets and Liabilities - Total assets as of March 31, 2025, were CNY 780,582,727.80, a decrease of 0.50% compared to the end of 2024[10] - The company's total liabilities to assets ratio decreased to 17.58% from 21.10% year-over-year, indicating improved financial stability[10] - The company's total liabilities decreased to 137,195,190.16 CNY from 165,560,862.70 CNY, a decline of approximately 17.1%[35] - The company's equity attributable to shareholders increased to 643,591,772.33 CNY from 619,148,692.83 CNY, reflecting an increase of about 3.9%[35] - Accounts receivable decreased to 65,354,113.44 CNY from 72,875,867.71 CNY, indicating a reduction of about 10.3%[33] Research and Development - Research and development expenses rose by 39.92% to CNY 5,709,516.26, reflecting the company's commitment to innovation[12] - Research and development expenses increased to CNY 4,586,700.60 in Q1 2025 from CNY 3,449,147.73 in Q1 2024, marking a rise of 32.9%[43] Shareholder Information - The total number of unrestricted shares is 48,447,400, accounting for 65.69% of the total share capital[17] - The total number of restricted shares is 25,306,600, representing 34.31% of the total share capital[18] - The largest shareholder, Wu Ping, holds 19,590,000 shares, which is 26.56% of the total shares[19] - The second-largest shareholder, Li Li, owns 10,400,000 shares, equivalent to 14.10% of the total shares[19] - The total number of shares outstanding is 73,754,000[18] - The total number of shares held by the top ten shareholders is 52,987,400, representing 71.84% of the total shares[20] Government Subsidies and Other Income - The company reported a significant increase in government subsidies, which rose by 466.82% to CNY 6,259,318.66, contributing positively to financial performance[12] - Other income increased to CNY 5,898,965.28 in Q1 2025 from CNY 821,071.06 in Q1 2024, indicating a substantial growth of 619.5%[43] Debt and Commitments - The company repaid 20,000,000.00 CNY in debt during Q1 2025, compared to no repayments in Q1 2024, reflecting a strategic focus on debt reduction[48] - The company has no major litigation or arbitration matters during the reporting period[24] - The company has no new commitments during the reporting period, maintaining previously disclosed commitments[28]

2024 年年度权益分派实施公告 证券代码：839273 证券简称：一致魔芋 公告编号：2025-057 湖北一致魔芋生物科技股份有限公司 以公司股权登记日应分配股数 73,586,018 股为基数（应分配总股数等于股权 登记日总股本 73,754,000 股减去回购的股份 167,982 股，根据《公司法》等规定， 公司持有的本公司股份不得分配利润），向参与分配的股东每 10 股转增 4 股，（其 中以股票发行溢价形成的资本公积金每 10 股转增 4 股，不需要纳税；以其他资 本公积每 10 股转增 0 股，需要纳税），每 10 股派 5 元人民币现金。分红前本公 司总股本为 73,754,000 股，分红后总股本增至 103,188,407 股。 2、扣税说明 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 湖北一致魔芋生物科技股份有限公司 2024 年年度权益分派方案已获 2025 年 4 月 15 日召开的股东大会审议通过，本次实施分配方案距离股东大会审议通 过的时间未超过两个月。 现将权益分派 ...

股票活跃度来看，今日可交易的北交所个股中，换手率超10%的有67只，其中，15股换手率超20%，换 手率在5%~10%之间的有89只，换手率在1%~5%之间的有105只。全天换手率居前的股票有华光源海、 广道数字、泰鹏智能等，换手率分别为59.67%、31.38%、30.84%。（数据宝） 北交所个股今日成交明细 | 代码 | 简称 | 收盘价（元） | 涨跌幅（%） | 换手率（%） | 成交额（万元） | | --- | --- | --- | --- | --- | --- | | 830799 | 艾融软件 | 61.58 | 4.67 | 15.58 | 122261.66 | | 920029 | 开发科技 | 121.88 | 3.30 | 23.09 | 87519.49 | | 920116 | 星图测控 | 85.52 | 0.65 | 21.11 | 64739.54 | | 839273 | 一致魔芋 | 68.40 | 2.61 | 17.29 | 54693.23 | | 872351 | 华光源海 | 25.48 | 12.99 | 59.67 | 54121.92 | | 83 ...

证券时报·数据宝统计显示，近一个月共有18家北交所公司获机构调研，调研机构类型显示，券商共对 17家公司进行调研；基金调研14家；阳光私募调研13家；保险调研10家；海外机构调研2家。 机构调研榜单中，民士达参与调研的机构合计达139家，最受关注；其次是一致魔芋、利通科技、奥迪 威，参与调研的机构分别有137家、77家、65家。 按申万行业分类，获机构调研的北交所公司分属于10个行业，机械设备、电子、基础化工等行业较为集 中，分别有5家、4家、2家公司上榜。 机构调研次数来看，一致魔芋机构调研最为密集，共获机构6次调研。民士达、利通科技、朗鸿科技等 机构调研也较为密集，均被机构调研2次。 根据调研日期截止日统计，近一个月（3月23日至4月22日），共有18家北交所公司获机构调研，其中， 民士达最受关注，参与调研的机构有139家。 近一个月机构调研股一览 | 代码 | 简称 | 机构家数 | 调研次数 | 最新收盘价（元） | 其间涨跌幅（%） | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | 833394 | 民士达 | 139 | 2 | 47.9 ...

Group 1: Company Development Focus for 2025 - Accelerate the construction of fundraising projects [4] - Increase R&D investment in konjac powder applications and expand its market share [4] - Focus on expanding markets for konjac products such as konjac素毛肚, konjac tea ingredients, and dietary fiber [4] - Deepen cooperation with key clients to enhance composite colloid technology advantages [4] - Promote the steady growth of the self-owned brand "Magic Brother" in tourism channels and online platforms [4] Group 2: Supply and Market Insights - High enthusiasm for konjac planting among farmers, with expected growth in planting area [5] - Supply-side growth is limited due to specific growing conditions and climate impact [5] - The konjac industry will explore markets focusing on health, functionality, environmental sustainability, and globalization [6] Group 3: Health Benefits and Product Information - Konjac is rich in soluble dietary fiber, beneficial for lowering blood lipids, regulating sugar metabolism, and improving gut function [7] - The shelf life of konjac powder is 18 months, while processed konjac gel can last up to 24 months [8] Group 4: Financial and Supply Chain Management - The company plans to gradually transmit cost pressures through a "cost-plus pricing" strategy to maintain stable gross margins [9] - Unique supply chain management through equipment leasing, technical support, and capacity locking with reputable cooperatives [10]

Group 1 - In the past month (from March 22 to April 21), 17 companies listed on the Beijing Stock Exchange (BSE) received institutional research, with Minshida being the most notable, attracting 139 participating institutions [1] - The types of institutions conducting research include 16 brokerages, 13 funds, 12 private equity firms, 9 insurance companies, and 2 overseas institutions [1] - The companies that received the most attention were Minshida, Yizhi Moyu, Litong Technology, and Audiwei, with 139, 124, 77, and 65 participating institutions respectively [1] Group 2 - The average stock price of the companies that received institutional research increased by 18.31% over the past month, with notable gainers including Yizhi Moyu (up 148.08%), Minshida (up 87.63%), and Jikang Instruments (up 32.68%) [2] - The average daily turnover rate for the researched companies was 7.71%, with the highest rates recorded for Zhongke Meiling (16.91%), Minshida (16.01%), and Guohang Yuanyang (15.15%) [2] - As of April 21, the average market capitalization of all companies on the BSE was 2.916 billion yuan, while the average market capitalization of the researched companies was 3.461 billion yuan, with Minshida, Hualing Co., and Fujida leading in market value [2]

五矿证券有限公司 关于湖北一致魔芋生物科技股份有限公司 使用闲置募集资金暂时补充流动资金的专项核查意见 五矿证券有限公司（以下简称"五矿证券 "、"保荐机构 "）作为湖北 一致魔芋生物科技股份有限公司（以下简称"一致魔芋 "或"公司 "）的保 荐机构，根据《证券发行上市保荐业务管理办法》《北京证券交易所股票上市 规则 （试行）》《北京证券交易所证券发行上市保荐业务管理细则》《北京证 券交易所 上市公司持续监管办法（试行）》等有关规定，对一致魔芋使用闲置 募集资金 暂时补充流动资金发表专项意见如下： 一、募集资金基本情况 2023 年 2 月 7 日，湖北一致魔芋生物科技股份有限公司（以下简称"一致 魔芋"）发行普通股 13,500,000 股，发行方式为定价发行，发行价格为 11.38 元 /股，募集资金总额为 153,650,000 元，募集资金净额为 139,485,657.62 元，到账 时间为 2023 年 2 月 10 日。公司因行使超额配售选择权取得的募集资金净额为 21,609,462.73 元，到账时间为 2023 年 3 月 23 日。 二、募集资金使用情况 （一）募集资金使用情况和存储的具 ...

证券代码：839273 证券简称：一致魔芋 公告编号：2025-050 湖北一致魔芋生物科技股份有限公司 使用闲置募集资金暂时补充流动资金公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、募集资金基本情况 2023 年 2 月 7 日，湖北一致魔芋生物科技股份有限公司（以下简称"一致 魔芋"）发行普通股 13,500,000 股，发行方式为定价发行，发行价格为 11.38 元/ 股，募集资金总额为 153,650,000 元，募集资金净额为 139,485,657.62 元，到账 时间为 2023 年 2 月 10 日。公司因行使超额配售选择权取得的募集资金净额为 21,609,462.73 元，到账时间为 2023 年 3 月 23 日。 二、募集资金使用情况 （一）募集资金使用情况和存储的具体情况 截至 2025 年 3 月 31 日，公司上述发行股份的募集资金使用情况具体如下： 单位：万元 | 序号 | 募集资金用 | | 募集资金计 划投资总额 | 累计投入募 | 投入进度（%） | | ...

湖北陈守邦律师事务所 关于湖北一致魔芋生物科技股份有限公司 2024 年年度股东大会的 法律意见书 l 北陈守邦社师? CHENSHOUBANG LAWFIRM - HUBEI 地址：湖北省宜昌市发展大道 57-6 号三峡云计算中心 B 座 17 层 电话: 0717-6900007 邮编：443005 湖北陈守邦律师事务所 法律意见书 湖北陈守邦律师事务所 关于湖北一致魔芋生物科技股份有限公司 2024 年年度股东大会的 法律意见书 致:湖北一致魔芋生物科技股份有限公司 湖北陈守邦律师事务所（以下简称"本所"）接受湖北一致魔芋生物科技股 份有限公司（以下简称"公司"）的委托,根据《中华人民共和国公司法》(以下 简称"《公司法》")、《中华人民共和国证券法》(以下简称"《证券法》") 等法律、 法规、规章和规范性文件以及《湖北一致魔芋生物科技股份有限公司章程》(以 下简称"《公司章程》")的相关规定,指派律师列席公司 2024 年年度股东大会 (以 下简称"本次股东大会"),对本次股东大会相关事项进行见证,并依法出具本法 律意见书。 本法律意见书仅就本次股东大会的召集和召开程序、出席本次股东大会现场 会议人员 ...